CCDC6 and cancer: Since the HR defect is accompanied by sensitivity to PARP inhibitors, we aimed to characterise and quantify the outcomes of CCDC6 downregulation on olaparib sensitivity in cancer testicular cells by measuring cellular metabolic activity as an indicator of cell viability.